September 26, 2017: Sydnexis, Inc. of San Diego, CA, obtained U.S. Patent No. 9,770,447, “Ophthalmic composition”.
Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
Claim 1 of the patent reads:
1. An ophthalmic composition, comprising one and no more than one ophthalmic agent, and deuterated water, at a pD of from about 4.2 to about 7.9, wherein the ophthalmic agent consists of atropine, atropine sulfate, or a combination thereof, at a concentration of from about 0.001 wt % to about 0.03 wt %.
The patent may be viewed at the USPTO website at http://pdfpiw.uspto.gov/.piw?Docid=09770447.